SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Oxford GlycoSciences Plc
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (326)1/28/2003 12:34:53 AM
From: scaram(o)uche  Read Replies (1) of 469
 
This week's BioCentury, page one........

With the merger plans of Cambridge
Antibody Group plc and Oxford Glyco-
Sciences plc, CEOs Peter Chambre and
David Ebsworth are not only creating one
of the best-financed biotech companies in
Europe, but they are also providing a
catalyst for investors to reconsider a U.K.
sector that is poised to release an abundance
of product news in 2003.

Until last week’s news from Cambridge
Antibody (LSE:CAT; CATG, Melbourn)
and Oxford GlycoSciences (LSE:OGS:
OGSI, Oxford), the British biotech sector
had looked to be in desperate straits. The
BioCentury London index fell 57% last
year, to a level last seen when the index hit
its all-time low in the summer of 1994 (see
“U.K. Scrapes the Floor,” A2).
But the U.K. group has more going for
it than many give it credit for.........

(continues, thanks RS!)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News